Pharmacokinetics and therapeutic drug monitoring of gentamicin in the elderly

Clinical Pharmacokinetics

Volumn 37, Issue 4, 1999, Pages 331-341

  Triggs, Edward ^a   Charles, Bruce ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; BETA LACTAM ANTIBIOTIC; CISPLATIN; FOSCARNET; FUROSEMIDE; GENTAMICIN; NONSTEROID ANTIINFLAMMATORY AGENT; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INACTIVATION; DRUG MONITORING; GRAM NEGATIVE INFECTION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; AGING; ANTI-INFECTIVE AGENTS; DRUG MONITORING; GENTAMICINS; HUMANS;

EID: 0032724856     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199937040-00004     Document Type: Article

References (61)

1. 1. Mayersohn MB. Special pharmacokinetic considerations in the elderly. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics. Principles of therapeutic drug monitoring, 3rd ed. Vancouver (WA): Applied Therapeutics, Inc., 1992: 9.1-9.43
2. 2. Norma DC, Toledo SD. Infections in elderly persons. Clin Geriatr Med 1992; 8: 713-9
3. 3. Zaske DE. Aminoglycosides. In: Yoshikawa TT, Norman DC, editors. Antimicrobial therapy in the elderly patient. New York: Marcel Dekker Inc., 1994: 183-235
4. 4. Crossley KB, Peterson KB. Infections in the elderly. Clin Infect Dis 1996; 22: 209-15
5. 5. Hustinx WNM, Hoepelman IM, 1993. Aminoglycoside regimens: is once a day enough? Clin Pharmacokinet 1993; 25: 427-32
6. 6. Rowe JW, Besdine RW. Approach to the elderly patient: physiologic considerations. In: Vestal RE, editor. Drug treatment in the elderly. Sydney: Adis International Ltd., 1984; 3-11
7. 7. Turner N, Scarpace PJ, Lowenthal DT. Geriatric pharmacology: basic and clinical considerations. Ann Rev Pharmacol 1992; 32: 271-302
8. 8. Hayes MJ, Langman MJS, Short AH. Changes in drug metabolism with increasing age: phenytoin clearance and protein binding. Br J Clin Pharmacol 1975; 2: 73-9
9. 9. Veering BT, Burm AGL, Souverijn JHM, et al. The effect of age on serum concentrations of albumin and alpha-acid glycoprotein. Br J Clin Pharmacol 1990; 29: 201-6
10. 10. Shock NW, Yiengst MJ, Norris AH, et al. Age differences in the water content of the body as related to basal oxygen consumption in males. J Gerontol 1963; 18: 1-8
11. 11. Greenblatt DJ, Divoll M, Abernethy DR, et al. Antipyrine kinetics in the elderly: prediction of age-related changes in benzodiazepine oxidizing capacity. J Pharmacol Exp Ther 1982; 220: 120-6
12. 12. Forbes GB, Reina JC. Adult lean body mass declines with age: some longitudinal observations. Metabolism 1970; 19: 653-63
13. 13. Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow and tubular secretory capacity in adult males. J Clin Invest 1950; 29: 496-507
14. 14. Macis-Munez JF, Cameron JS. Renal function in the elderly. In: Cameron S, Davidson A, editors. Oxford textbook of clinical nephrology. Oxford: Oxford Medical Publishers, 1992; 56-70
15. 15. Bender AD. The effect of increasing age on the distribution of peripheral blood flow in man. J Am Geriatr Soc 1965; 13: 192-98
16. 16. Rodeheffer RJ, Gerstenblith G, Becker LC, et al. Exercise cardiac output is maintained with advancing age in healthy human subjects: cardiac dilatation and increased stroke volume compensate for a diminished heart rate. Circulation 1984; 69: 203-135
17. 17. Hoey LL, Tschida SJ, Rotschafer JC, et al. Wide variation in single, daily-dose aminoglycoside pharmacokinetics inpatients with burn injuries. J Burn Care Rehabil 1997; 18: 116-24
18. 18. Lackner TE, Birge S. Accuracy of pharmacokinetic dose determination of gentamicin in geriatric patients. DICP 1990; 24: 29-32
19. 19. El-Sayed YM. Correlation between nephrotoxicity and pharmacokinetic parameters of gentamicin. J Clin Pharm Ther 1994; 19: 267-71
20. 20. Peterson AK, Duffull SB. Population analysis of once-daily dosing of gentamicin in patients with neutropenia. Aust NZ J Med 1998; 28: 311-5
21. 21. Ordovas JP, Ronchera CL, Poveda JL, et al. Selection of optimal prophylactic aminoglycoside dosage in cancer patients: population pharmacokinetic approaches. J Clin Pharm Ther 1994; 19: 47-56
22. 22. Bertino Jr JS, Booker LA, Franck P, et al. Gentamicin pharmacokinetics in patients with malignacies. Antimicrob Agents Chemother 1991; 35: 1501-3
23. 23. Fiumara A-M, Sidhu J, Charles BG. Pharmacokinetic approaches for the prediction of serum gentamicin in the elderly. Aust J Hosp Pharm 1993; 23: 304-9
24. 24. Zaske DE, Irvine P, Strand LM, et al. Wide variations in gentamicin dose requirements for geriatric patients. JAMA 1982; 248: 3112-6
25. 25. Gatell JM, Ferran F, Araujo V, et al. Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agents Chemother 1987; 31: 1383-7
26. 26. Sawyers CL, Moore RD, Lerner SA, et al. A model for predicting nephrotoxicity in patients treated with aminoglycosides. J Infect Dis 1986; 153: 1062-8
27. 27. Bauer LA, Blouin RA. Gentamicin pharmacokinetics; effect of aging in patients with normal renal function. J Am Geriatr Soc 1982; 30: 309-11
28. 28. Matzke GR, Jameson JJ, Halstenson CE. Gentamicin disposition in young and elderly patients with various degrees of renal function. J Clin Pharmacol 1987; 27: 216-20
29. 29. Begg EJ, Barclay ML. Aminoglycosides: 50 years on. Br J Clin Pharmacol 1995; 39: 597-603
30. 30. Henderson JL, Polk RE, Kline BJ. In vitro interaction of gentamicin, tobramycin and netilmicin by carbenicillin, azlocillin, or mezlocillin. Am J Hosp Pharm 1981; 38: 1167-70
31. 31. Kradjan WA, Burger R. In vivo inactivation of gentamicin by carbenicillin and ticarcillin. Arch Intern Med 1980; 140: 1668-70
32. 32. Halstenson CE, Wong MO, Herman CS, et al. Effect of concomitant administration of piperacillin on the disposition of isepamicin and gentamicin in patients with end-stage renal disease. Antimicrob Agents Chemother 1992; 36: 1832-6
33. 33. Vestal RF. Pharmacology and aging. J Am Geriatr Soc 1982; 30: 191-200
34. 34. Mörike K, Schwab M, Klotz U. Use of aminoglycosides in elderly patients. Drugs Aging 1997; 10: 259-77
35. 35. Bodey GP. Antibiotics in patients with neutropenia. Arch Intern Med 1984; 44: 1845-51
36. 36. Etzel JV, Nafziger AN, Bertino Jr JS. Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemia. Antimicrob Agents Chemother 1992; 36: 679-81
37. 37. Triginer C, Izquierdo I, Fernandez R, et al. Gentamicin volume of distribution in critically ill septic patients. Intens Care Med 1990; 16: 303-6
38. 38. Bjornsson TD. Use of serum creatinine concentrations to determine renal function. Clin Pharmacokinet 1979; 4: 200-22
39. 39. Drusano GL, Muncie HL, Hoopes JL, et al. Commonly used methods of estimating creatinine clearance are inadequate for elderly debilitated nursing home patients. J Am Geriatr Soc 1988; 40: 2175-80
40. 40. Beck CL, Pucino F, Carlson JD, et al. Evaluation of creatinine clearance estimation in an elderly male population. Pharmacotherapy 1988; 8: 183-8
41. 41. Reichley RM, Ritchie DJ, Bailey TC. Analysis of various creatinine clearance formulas in predicting gentamicin elimination in patients with low serum creatinine. Pharmacotherapy 1995; 15: 625-30
42. 42. Begg EJ, Barclay ML, Kirkpatrick CJM. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 1999; 47: 23-30
43. 43. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39: 650-55
44. 44. Koo J, Tight R, Rajkumar V, et al. Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients. Am J Med 1996; 101: 177-83
45. 45. Christensen S, Ladefoged K, Frimodt-Møller N. Experience with once daily dosing of gentamicin: considerations regarding dosing and monitoring. Chemotherapy 1997; 43: 442-50
46. 46. Paterson DL, Robson JMB, Wagener MM. Risk factors for toxicity in elderly patients given aminoglycosides once daily. J Gen Intern Med 1998; 13: 735-9
47. 47. Cronberg S, Nordström L. Simplified monitoring of aminoglycosidc treatment. Scand J Infect Dis 1191; Suppl. 74: 274-9
48. 48. Marinkovic S, Urick P, Mian H, et al. Renal toxicity, clinical efficacy and cost using qd aminoglycoside therapy in elderly patients with urosepsis [abstract]. J Urol 1998; 159 (5 Suppl.) : 275
49. 49. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
50. 50. Finnell DL, Davis GA, Cropp CD, et al. Validation of the Hartford nomogram in trauma surgery patients. Ann Pharmacother 1998; 32: 417-21
51. 51. El Bakri F, Pallett A, Smith AG, et al. Ototoxicity induced by once-daily gentamicin. Lancet 1998 May 9; 351: 1407-8
52. 52. Singer C, Smith C, Krieff D. Once-daily aminoglycoside therapy: potential ototoxicity. Antimicrob Agents Chemother 1996; 40: 2209-11
53. 53. Medicus-Bringa M, Ward G, Rice M. Once-daily versus pharmacokinetic dosing of aminoglycosides [letter]. Am J Med 1997; 103: 328
54. 54. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39: 605-9
55. 55. Barclay ML, Duffull SB, Begg EJ, et al. Experience of once-daily aminoglycoside dosing using a target area under the concentration time curve. Aust NZ J Med 1995; 25: 230-5
56. 56. Duffull SB, Kirkpatrick CMJ, Begg EJ. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens. Br J Clin Pharmacol 1997; 43: 125-35
57. 57. Garrelts JC. Exploration of once-daily dosing of aminoglycosides through Bayesian simulation. Pharmacotherapy 1996; 16: 286-94
58. 58. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993; 32: 325-34
59. 59. Bertino JS, Booker LA, Franck PA, et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualised pharmacokinetic monitoring. J Infect Dis 1993; 167: 173-9
60. 60. Aminoglycosides still an important option for the treatment of infections in the elderly. Drugs Ther Perspectives 1998; 11: 8-10
61. 61. Prins JM, Koopmans RP, Buller HR, et al. Easier monitoring of aminoglycoside therapy with once-daily dosing schedules. Eur J Clin Microbiol Infect Dis 1995; 14: 531-5